The average gap between NHI prices and the market prices of listed medicines in Japan stood at a preliminary 5.2%…
HOME > BUSINESS
BUSINESS
- New Granule Formulation of Fosrenol Obtains Approval: Bayer Yakuhin
February 3, 2012
- Janssen Files Application for Additional Subcutaneous Administration of Velcade
February 2, 2012
- Chugai Pharmaceutical to Promote Executive VP Kosaka as President and COO
February 2, 2012
- Astellas, UCB Form Partnership for Rheumatoid Arthritis Treatment Awaiting Approval
February 2, 2012
- Kyowa Kirin Sees Nesp as Core of Its Asian Strategy: President Matsuda
February 2, 2012
- Maruho, Asahi Kasei Pharma File Application for Add’l Indication of Herpes Simplex for Famvir
February 2, 2012
- Nycomed Acquisition Contributes to 4.3% Growth in Sales for April-December 2011: Takeda
February 2, 2012
- Daiichi Sankyo Says “No Major Impact” from Ranbaxy’s Relinquishment of Marketing Exclusivity
February 1, 2012
- Shuichi Watanabe to Become President, Sadatake Kumakura Chairman: Medipal HD
February 1, 2012
- Apr-Dec Net Profits Down 78% due to Ranbaxy Settlement Fee: Daiichi Sankyo
February 1, 2012
- Kyowa Hakko Kirin Withdraws Application for Additional Indication for Nesp
February 1, 2012
- Kyowa Kirin Development Chief Hanai Set to Become Company President
February 1, 2012
- Apr-Dec Sales Drop 1.2% due to Impact of Great East Japan Earthquake: MTPC
February 1, 2012
- Shared Awareness of Goals Needed in Industry-Academia Collaborations: Dr Teshirogi of Shionogi
February 1, 2012
- Patient Enrollment for All-case PMS for Imusera, Telavic Making Steady Progress: MTPC
February 1, 2012
- Mochida Pharmaceutical Sees Double-Digit Growth in Apr-Dec on Growth of Epadel
January 31, 2012
- DSP to Set Up New Chemical Research Building at Osaka Research Center
January 31, 2012
- Apr-Dec Sales Drop 8.5% due to Slump of US Subsidiary: Shionogi
January 31, 2012
- Shionogi to Set Up Development Site in Europe to Accelerate Global Development
January 31, 2012
- Takeda Initiates Domestic PIII Clinical Trials for New Prostate Cancer Drug, TAK-700
January 30, 2012
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…